Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1157

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1157
---
 period of time after filing, and some
remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. We or our licensors may also become involved in proceedings regarding our patents, including patent infringement lawsuits,
interference or derivation proceedings, oppositions, and inter partes and post-grant review proceedings before the USPTO, the European
Patent Office and other non-U.S. patent offices.

Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.

Our success will depend in part
on our ability to commercialize our product candidates without infringing the proprietary rights of others. While some of the intellectual
property utilized in our product candidates is owned, some is licensed from our licensors, who hold patents and provisional patents in
their names. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist or
could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with respect
to our technology. We also cannot be sure that patents or provisional patents filed by others are valid or will be upheld if challenged.
It is possible that there are additional patents that may cover certain other aspects of technology used in our product candidates that
is not covered by our licensed intellectual property. If our licensed technology or other subject matter are claimed under other United
States patents or other international patents or are otherwise protected by third party proprietary rights,

36

we or our licensors may be
subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be
required to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances
that we would be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained on
commercially reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative or obtain
needed licenses could have significant adverse consequences to the development of our pipeline. Adverse consequences include delays in
marketing some or all of our product candidates based on our technology or the inability to proceed with the development, manufacture
or sale of products requiring such licenses. If we defend ourselves against charges of patent infringement or to protect our proprietary
rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically
protracted with no certainty